Semaglutide Significantly Reduces Cardiovascular Events in Overweight Adults

Cardiovascular disease (CVD) remains the leading cause of mortality globally, with obesity being a major contributing risk factor. While weight loss is known to improve various metabolic parameters, it has been unclear whether pharmacologically induced weight loss in individuals without diabetes directly translates into a reduction in hard cardiovascular outcomes. This study, the SELECT trial, specifically addresses whether semaglutide, a GLP-1 receptor agonist, can reduce major adverse cardiovascular events (MACE) in overweight or obese individuals with established CVD but without diabetes.

The trial demonstrated a significant reduction in the primary composite endpoint of MACE in the semaglutide group. Participants receiving semaglutide 2.4 mg experienced a 20% reduction in MACE compared to the placebo group (Hazard Ratio 0.80, 95% CI 0.72-0.90, p<0.001). This reduction was consistent across all components of the primary endpoint. Furthermore, semaglutide led to substantial weight loss, with a mean change in body weight of -15.3% from baseline in the semaglutide group versus -2.6% in the placebo group. The most significant finding was a 20% reduction in Major Adverse Cardiovascular Events (MACE) in participants receiving semaglutide 2.4 mg compared to placebo, establishing a direct cardiovascular benefit beyond weight loss alone. Cardiovascular death was reduced by 15% (HR 0.85, 95% CI 0.71-1.01) and all-cause mortality by 19% (HR 0.81, 95% CI 0.69-0.95) in the semaglutide group, though the cardiovascular death reduction did not reach statistical significance.